SCHEMBL21595533

SCHEMBL21595533

CCOc1ccc(C(=O)Nc2ccncc2)nc1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.70
KMT2A Q03164 1/20 0.66
SMN1; SMN2 Q16637 7/20 0.65
RAB9A P51151 6/20 0.65
NPC1 O15118 5/20 0.65
TP53 P04637 3/20 0.65
POLB P06746 1/20 0.65
PKM P14618 3/20 0.60
KDM4E B2RXH2 2/20 0.60
MITF O75030 1/20 0.60
HTT P42858 2/20 0.60
P4HTM Q9NXG6 2/20 0.59
STAT3 P40763 1/20 0.56
MAPT P10636 3/20 0.54
GAA P10253 1/20 0.54
NAMPT P43490 1/20 0.53
ALDH1A1 P00352 2/20 0.51
HPGD P15428 1/20 0.51
RXFP1 Q9HBX9 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21595507 0.87 NPC1 (0.66) LMNAKMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL21595592 0.85 TSHR (0.69) KMT2ASMN1; SMN2RAB9ANPC1TP53
SCHEMBL21595502 0.84 MAPT (0.64) LMNAKMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL29013030 0.82 LMNA (1.00) LMNAKMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL16496746 0.79 RAB9A (1.00) LMNAKMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL30763041 0.79 FADS1 (0.67) KMT2ASMN1; SMN2RAB9ANPC1TP53
SCHEMBL21595535 0.79 FADS1 (0.67) KMT2ASMN1; SMN2RAB9ANPC1TP53
SCHEMBL30763155 0.78 NPC1 (0.61) LMNAKMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL21595562 0.78 NPC1 (0.61) LMNAKMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL18496839 0.77 P4HTM (0.47) LMNAKMT2ASMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3810597-B1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS UNIV OSLO HF (NO) 2025-11-26 EP disclosed
US-11926614-B2 1,2,4-triazole derivatives as tankyrase inhibitors OSLO UNIVERSITETSSYKEHUS HF (NO) 2024-03-12 US disclosed
CN-112469714-B 1,2, 4-triazole derivatives as tankyrase inhibitors 奥斯陆大学国家医院 2024-03-01 CN disclosed
EP-3810597-A1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS Oslo Universitetssykehus HF (NO) 2021-04-28 EP disclosed
CN-112469714-A 1,2, 4-triazole derivatives as tankyrase inhibitors 奥斯陆大学国家医院 2021-03-09 CN disclosed
WO-2019243822-A1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS OSLO UNIVERSITETSSYKEHUS HF (NO) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11926614-B2 1,2,4-triazole derivatives as tankyrase inhibitors GBA3, CBR3, TECR LMNA 1564/4885KMT2A 4273/4885SMN1; SMN2 4006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.